コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 loped respiratory disease, and one developed gastrointestinal disease).
2 both inflammatory and malignancy associated gastrointestinal disease.
3 s well as many cases of non-food-borne human gastrointestinal disease.
4 ic illnesses such as respiratory distress or gastrointestinal disease.
5 those with no presenting signs suggestive of gastrointestinal disease.
6 and return to active growth, they can cause gastrointestinal disease.
7 for multiple baseline risk factors for upper gastrointestinal disease.
8 erved that feces often smell abnormal during gastrointestinal disease.
9 he feces of healthy donors and patients with gastrointestinal disease.
10 imicry used to promote EPEC pathogenesis and gastrointestinal disease.
11 lammatory models of cardiac, neurologic, and gastrointestinal disease.
12 ne of the most frequent causes of nosocomial gastrointestinal disease.
13 oxibs among their patients with a history of gastrointestinal disease.
14 ccur in the intestines during CPE-associated gastrointestinal disease.
15 an important step in its ability to initiate gastrointestinal disease.
16 by contribute to the diarrhea of CPE-induced gastrointestinal disease.
17 e, high intakes of supplemental iron, or any gastrointestinal disease.
18 otoxic shock, with the development of severe gastrointestinal disease.
19 onse associated with cytomegalovirus-induced gastrointestinal disease.
20 ram-negative bacterium, is a common cause of gastrointestinal disease.
21 spiral bacterium, is a common cause of human gastrointestinal disease.
22 8 MAPK for the treatment of visceral pain in gastrointestinal disease.
23 ity of zonulin in obese adults free of lower gastrointestinal disease.
24 argets for the treatment of visceral pain in gastrointestinal disease.
25 n inhalation exposures and the risk of upper gastrointestinal disease.
26 living therapeutic interventions for chronic gastrointestinal disease.
27 nts mostly in areas with high occurrences of gastrointestinal disease.
28 tal muscle vasculitis, not cardiomyopathy or gastrointestinal disease.
29 part of the investigation and management of gastrointestinal disease.
30 use is a major contributor to the burden of gastrointestinal disease.
31 ms in the generation of visceral pain during gastrointestinal disease.
32 part of the investigation and management of gastrointestinal disease.
33 lution and an increased risk of exacerbating gastrointestinal disease.
34 hogen that plays a role in acute and chronic gastrointestinal disease.
35 ng platform for the study of inflammation in gastrointestinal disease.
36 in neonates, in some cases, without causing gastrointestinal disease.
37 with a change in bowel habit and no organic gastrointestinal disease.
38 isease, were classified as having no organic gastrointestinal disease.
39 verity of a plethora of illnesses, including gastrointestinal disease.
40 8 h of admission in a group of patients with gastrointestinal diseases.
41 e can potentially be used to protect against gastrointestinal diseases.
42 ved asthma control, and lower risk of select gastrointestinal diseases.
43 flammatory bowel diseases are costly chronic gastrointestinal diseases.
44 show promise for the treatment of pediatric gastrointestinal diseases.
45 y new ablative modality for the treatment of gastrointestinal diseases.
46 in the diagnosis and surveillance of various gastrointestinal diseases.
47 ess (chronic stress) often causes functional gastrointestinal diseases.
48 pment of new therapeutic strategies for many gastrointestinal diseases.
49 for its potential activity in a multitude of gastrointestinal diseases.
50 knowledge for future investigations of human gastrointestinal diseases.
51 y be useful for preventing cytokine-mediated gastrointestinal diseases.
52 ticle will review the role of polyphenols in gastrointestinal diseases.
53 he beneficial effects of polyphenols in many gastrointestinal diseases.
54 possible contribution to the pathogenesis of gastrointestinal diseases.
55 for cutaneous manifestations of inflammatory gastrointestinal diseases.
56 itis and may have therapeutic application in gastrointestinal diseases.
57 pict its potential role in the management of gastrointestinal diseases.
58 such a process that focuses on eosinophilic gastrointestinal diseases.
59 anges that may translate into treatments for gastrointestinal diseases.
60 een invoked as mediators of tissue injury in gastrointestinal diseases.
61 investigator to better understand and treat gastrointestinal diseases.
62 important for advancing therapies for common gastrointestinal diseases.
63 microbiome composition aspects seen in human gastrointestinal diseases.
64 py (CCE) has proven efficacy in a variety of gastrointestinal diseases.
65 represents a common manifestation of several gastrointestinal diseases.
66 a probiotic bacterium used to treat various gastrointestinal diseases.
67 of effective therapeutic strategies to treat gastrointestinal diseases.
68 patients with coexisting cardiovascular and gastrointestinal diseases.
69 the diagnosis and evaluation of treatment of gastrointestinal diseases.
70 , arthritis as well as neurodegenerative and gastrointestinal diseases.
71 l "dysbiosis" can be responsible for several gastrointestinal diseases.
72 e smoking, and particulate matter) and upper gastrointestinal diseases.
73 r supporting the diagnosis and management of gastrointestinal diseases.
74 ing claudin/CpE assembly to treat CpE-linked gastrointestinal diseases.
75 docrinal-, infectious-, cardiovascular-, and gastrointestinal diseases.
76 regenerative medicine and the study of human gastrointestinal diseases.
77 he mechanisms and management of eosinophilic gastrointestinal diseases.
78 eases as well as in a number of inflammatory gastrointestinal diseases.
79 early stages of development for treatment of gastrointestinal diseases.
80 including drug delivery in the treatment of gastrointestinal diseases.
81 acterium shown to be linked with a series of gastrointestinal diseases.
82 improved interventions to prevent and treat gastrointestinal diseases.
83 ity of new research approaches investigating gastrointestinal diseases.
84 argeted therapeutic options for a variety of gastrointestinal diseases.
85 cterization and pathophysiology of a host of gastrointestinal diseases.
86 ersial bacteria in the world causing diverse gastrointestinal diseases.
89 vs 13 % and 14 %, P < 0.001), had less other gastrointestinal diseases (8 % vs 40 % and 25 %, P = 0.0
91 sis is statistically associated with several gastrointestinal diseases, affecting their pathophysiolo
92 stem predicts the relative reporting rate of gastrointestinal disease amongst all presentations, and
93 f anti-transglutaminase 2 IgA is linked with gastrointestinal disease, an anti-transglutaminase 6 IgG
94 re associated with an increased incidence of gastrointestinal disease and AIDS-related mortality.
95 f endoscopically visible mucosal biofilms in gastrointestinal disease and associated changes in micro
98 tudy population included participants in the Gastrointestinal Disease and Endoscopy Registry (GIDER),
100 sts that development of a vaccine to prevent gastrointestinal disease and limit colonization is possi
101 n 30 days who were diagnosed with a surgical gastrointestinal disease and PN dependent for at least 2
102 nflammatory cytokine TNFalpha is elevated in gastrointestinal disease and sensitizes colonic afferent
103 57:H7 are a significant cause of hemorrhagic gastrointestinal disease and the hemolytic uremic syndro
104 ichia coli O157:H7, has been associated with gastrointestinal disease and the life-threatening sequel
105 A isolates causing both non-food-borne human gastrointestinal disease and veterinary disease carry th
107 alterations in the intestinal microbiome and gastrointestinal diseases and findings from clinical tri
110 al developments in the field of eosinophilic gastrointestinal diseases and the contribution of basic
113 t in colostrum, for the treatment of various gastrointestinal diseases and the relative merits of the
114 dd insights into relationships between these gastrointestinal diseases and their relationships with d
115 inavailable in English, those focused on non-gastrointestinal diseases and those that were duplicates
116 ts into the pathogenesis of common liver and gastrointestinal diseases and to new treatment strategie
117 f review discusses a variety of food-induced gastrointestinal diseases and will highlight the recent
118 5 fimbriae (from bacteria primarily causing gastrointestinal disease) and class 1 pili (from bacteri
119 articular, limb, or back pain, headaches, or gastrointestinal diseases) and their relationship with m
121 eal reflux disease (GERD) is the most common gastrointestinal disease, and the cost of health care an
122 gnificant factor in the pathogenesis in many gastrointestinal diseases, and is perhaps the most clini
123 system diseases, endocrine system diseases, gastrointestinal diseases, and respiratory tract disease
127 Reduced intestinal CD4 T cell numbers and gastrointestinal disease are common features of acquired
131 c profiling have been extensively studied in gastrointestinal diseases as potential diagnostic marker
132 l therapeutic strategies in the treatment of gastrointestinal diseases associated with altered IESC f
133 s available to inhibit apoptosis for various gastrointestinal diseases associated with cell death and
138 (PPIs) are widely used for the treatment of gastrointestinal diseases but have also been shown to be
139 This antibiotic may be effective for other gastrointestinal diseases, but more well designed clinic
140 altered iron distribution occur in multiple gastrointestinal diseases, but the importance and regula
141 ease (IBD) is one of the most common chronic gastrointestinal diseases, but the underlying molecular
142 mplicated in the pathogenesis of a number of gastrointestinal diseases, but we have limited understan
144 ted with malabsorption of macronutrients and gastrointestinal disease can impair copper uptake and co
145 l eggs, since approximately 80% of all human gastrointestinal diseases can be traced to contaminated
146 cular disease, diabetes, traumatic injuries, gastrointestinal diseases, cancers, and fetal alcohol sy
147 solates responsible for non-food-borne human gastrointestinal diseases carry a plasmid cpe gene.
149 Progress in the pharmacotherapy of pediatric gastrointestinal diseases continued during 1998 despite
150 Although poor sleep is common in numerous gastrointestinal diseases, data are scarce on the risk o
152 and their FLT results were compared to their gastrointestinal disease diagnoses at time of discharge.
153 Female gender and a pretransplant upper gastrointestinal disease diagnosis predicted posttranspl
154 e genus Shigella cause shigellosis, a severe gastrointestinal disease driven by bacterial colonizatio
161 sic biology and pathogenesis of eosinophilic gastrointestinal diseases (EGIDs) in addition to advance
164 ght loss, family history of selected organic gastrointestinal diseases, evidence of gastrointestinal
165 utoinflammatory episodes, including aphthae, gastrointestinal disease, febrile attacks, and small-ves
167 s and waterborne diseases, such as childhood gastrointestinal diseases; food insecurity, including re
170 up (p < 0001), 22 of 30 (73%) females in the gastrointestinal disease group (p < .008), but 11 of 37
176 obstructive pulmonary disease, eosinophilic gastrointestinal diseases, hyper-eosinophilic syndrome,
177 BPV), the causative agent of respiratory and gastrointestinal disease in cows, is the type member of
180 is now the most frequently reported cause of gastrointestinal disease in England and Wales, yet few i
181 r of novel Helicobacter spp. associated with gastrointestinal disease in humans and animals is rapidl
188 is associated with enhanced protection from gastrointestinal disease in infants, mediated in part by
190 tis (NEC) is the leading cause of death from gastrointestinal disease in newborn infants and is chara
191 and ulcerative colitis are common causes of gastrointestinal disease in northern Europe, affecting a
192 tis (NEC) is the leading cause of death from gastrointestinal disease in preterm infants and is chara
193 leading cause of gastrointestinal death from gastrointestinal disease in preterm infants, is characte
195 gastrointestinal tract, and the severity of gastrointestinal disease in SSc correlates with high mor
198 closely related to ST313 variants that cause gastrointestinal disease in the United Kingdom and Brazi
201 olonic diverticulitis is a common and costly gastrointestinal disease in Western countries, character
204 associated with signs of postwar cardiac and gastrointestinal disease (incidence risk ratio [IRR], 1.
206 mid and long-term evaluations, in different gastrointestinal diseases including achalasia, refractor
207 re now headed for clinical trials in several gastrointestinal diseases including inflammatory bowel d
208 d early life stress may increase the risk of gastrointestinal diseases including irritable bowel synd
210 eptor guanylyl cyclase C (GC-C) cause severe gastrointestinal disease, including meconium ileus, earl
211 n vitro model among caliciviruses that cause gastrointestinal disease, including members of the gener
212 od poisoning and several non-foodborne human gastrointestinal diseases, including antibiotic-associat
213 ated with cancer development in a variety of gastrointestinal diseases, including cholangiocarcinoma.
214 n (cpe) gene are an important cause of human gastrointestinal diseases, including food poisoning, ant
215 cycle arrest that has been involved in many gastrointestinal diseases, including human cholestatic l
216 l microbes to the gut may exacerbate various gastrointestinal diseases, including irritable bowel syn
217 ier function are associated with a number of gastrointestinal diseases, including neonatal necrotizin
218 d with several inflammatory and haemorrhagic gastrointestinal diseases, including oesophagitis (OR 1.
219 ase in biomarker pathways of respiratory and gastrointestinal disease inflammation, infection by coro
221 strointestinal tract and its relationship to gastrointestinal disease, interest has expanded to inclu
225 These data suggest that the SIV-associated gastrointestinal disease is associated with the presence
226 udies that attempted to quantify the risk of gastrointestinal disease linked to the consumption of ha
227 discusses CAM use in three types of chronic gastrointestinal diseases-liver disease, irritable bowel
228 The detection of pathogens associated with gastrointestinal disease may be important in certain pat
229 nt recipients with recurrent cytomegalovirus gastrointestinal disease may resolve their symptoms.
232 Barrett's metaplasia (N = 16), benign upper gastrointestinal diseases (N = 62), or a normal upper ga
233 otizing enterocolitis (NEC) is a devastating gastrointestinal disease of incompletely understood path
234 zing enterocolitis (NEC), a life-threatening gastrointestinal disease of premature infants characteri
235 otizing enterocolitis (NEC) is a devastating gastrointestinal disease of premature infants partly cau
236 and Eimeria, two major infectious agents of gastrointestinal diseases of poultry of economic importa
239 cluded from the study if they had coexisting gastrointestinal disease or had a substantial coexisting
241 CI 1.26, 1.85; P < 0.001), and pre-existing gastrointestinal disease (OR 1.48; 95% CI 1.22, 1.8; P <
242 of osteoarthritis (OR 2.6, 95% CI 1.7-3.8), gastrointestinal disease (OR 2.3, 95% CI 1.2-4.5), and c
243 rtunity Index (OR, 1.28; 99% CI, 1.05-1.56), gastrointestinal disease (OR, 1.33; 99% CI, 1.01-1.77),
244 not affected by gastrointestinal infections, gastrointestinal disease, or abdominal pain in the first
248 remia and endocarditis with various forms of gastrointestinal disease (primarily colonic cancers).
249 ht the genetic relationship between lung and gastrointestinal diseases, providing insights into the g
253 llected across 11 Consortium of Eosinophilic Gastrointestinal Disease Researchers sites (n = 311) and
254 enrolled across 9 Consortium of Eosinophilic Gastrointestinal Disease Researchers-associated sites.
260 size the impact of inhalational exposures on gastrointestinal disease risk, highlighting the need for
261 o inflammatory bowel disease or eosinophilic gastrointestinal disease showed the least benefit and in
265 ics, including medications intended to treat gastrointestinal diseases, such as antitumor necrosis fa
267 bute to peptic ulcer disease (PUD) and other gastrointestinal diseases, such as gastro-oesophageal re
271 ncy virus (SIV) infection is associated with gastrointestinal disease, systemic immune activation, an
273 e genus Shigella cause shigellosis, a severe gastrointestinal disease that is a major cause of diarrh
276 ome countries (LMICs) face a large burden of gastrointestinal diseases that benefit from prompt endos
277 ecommended evaluation and treatments for the gastrointestinal diseases that most commonly mimic the p
282 promotes the clinical manifestations of SSc gastrointestinal disease throughout the gastrointestinal
285 tory cytokine, in cytomegalovirus-associated gastrointestinal disease, we quantitated the level of TN
286 f oral antigen-induced eosinophil-associated gastrointestinal disease, we report the pathological con
287 tis, while more subjects without significant gastrointestinal disease were anemic on presentation.
290 Enterocytozoon bieneusi is known to cause a gastrointestinal disease whereas Encephalitozoon intesti
291 o-organisms increases the risk of infectious gastrointestinal disease which could potentially lead to
292 gitis is an increasingly recognized allergic gastrointestinal disease, which is becoming more common.
293 eral pain is a leading cause of morbidity in gastrointestinal diseases, which is exacerbated by the g
294 ive probiotics are an effective way to treat gastrointestinal diseases, which often face challenges i
295 diagnostic approach to several food-induced gastrointestinal diseases will be individually examined.
296 unctional or structural lung impairment, and gastrointestinal disease with or without malabsorption,
297 ost species to cause pandemic respiratory or gastrointestinal diseases with significant mortality in
299 he leading causes of hospital admission from gastrointestinal diseases, with approximately 300 000 em
300 Non-typhoidal Salmonella are associated with gastrointestinal disease worldwide and invasive disease